3 results
HV cohort 1Primary Objectives* To characterize the local tolerability of topical bimiralisib after 21 days* To characterize the systemic PK of topical bimiralisib after 21 daysSecondary Objective* To characterize the safety of topical bimiralisib…
Primary ObjectiveThe primary objective is to determine if maintenance treatment with resminostat increases progression free survival (PFS) compared to placebo in patients with advanced stage (Stage IIB IVB) MF or SS that have achieved disease…
1. To determine risk factors for BIA-ALCL in women with silicone breast implants. The associations between demographic-, reproductive- and lifestyle characteristics and BIA-ALCL risk among women with breast implants will be investigated. Furthermore…